Araris Biotech

Araris Biotech AG (Araris) is a biotechnology startup. Their goal is to provide a breakthrough technology platform for developing the next generation of safe and effective antibody-drug conjugates (ADCs) to treat various diseases. Their biotechnology platform can connect any drug payload to "off-the-shelf" antibodies without prior antibody engineering. Results show that, compared to FDA-approved ADCs, these ADCs exhibit high activity at lower doses and demonstrate an improved therapeutic index.